Latest News, Press Releases & Events

Spyryx Biosciences Expands with Election of Roger Jeffs, PhD as Independent Director

– Recognized Biotech Leader With Extensive Experience in Respiratory Product Development and Rare Diseases DURHAM, N.C., Jan. 16, 2018 /PRNewswire/ — Spyryx Biosciences, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for severe pulmonary diseases, announced today the election of Dr. Roger Jeffs as a member of the Company’s board of directors. Dr. Jeffs brings […]

Continue Reading

Positive Pre-Clinical Data Supporting SPX-101 to be Presented at the North American Cystic Fibrosis Conference

4 Posters detail SPX-101’s unique mechanism and potential to provide clinically meaningful benefit for all people with cystic fibrosis DURHAM, N.C., Nov. 1, 2017 /PRNewswire/ — Spyryx Biosciences, Inc., will share positive data this week highlighting additional insights into the mechanism of action and pharmacological importance of SPX-101, the Company’s pipeline therapeutic treatment for cystic fibrosis […]

Continue Reading

HOPE-1 Clinical Trial for SPX-101 Is Enrolling CF Patients in Canada and Europe

CYSTIC FIBROSIS NEWS TODAY by Ana Belo Van Wijk, PhD – The first patient has been enrolled and dosed in the HOPE-1 Phase 2 clinical trial evaluating Spyryx Biosciences‘ investigational drug SPX-101 as a treatment for cystic fibrosis (CF). The HOPE-1 study (NCT03229252) will take place in Alberta and Ontario in Canada, the United Kingdom, France, and Portugal. […]

Continue Reading